Dewpoint Therapeutics
Angela graduated magna cum laude from Northeastern University in May 2021 with a Bachelor of Science in Cell and Molecular Biology. During her time at Northeastern, she was lucky to have three 6-month, full-time co-op experiences—in the Chiu Lab at Harvard Medical School (2018), at Morphic Therapeutic (2019), and at UCB Ra Pharmaceuticals (2020)—where she developed lab skills and scientific and industry knowledge. She also had the opportunity to study abroad at the University of Dundee in Scotland in Spring 2020, where she took cell signaling and immunology classes and conducted a 5-week lab research project. Angela is excited to join Dewpoint to learn more about biological condensates and the diseases they are involved in and to contribute to drug discovery efforts in the Rare Disease group. In her free time, she loves traveling, observing nature, singing, cooking/trying new foods, and trying new physical activities.
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.